马应龙药业集团股份有限公司关于子公司获得药品注册证书的公告

Group 1 - The company announced that its subsidiary, Jiangxi Mayinglong Meikang Pharmaceutical Co., Ltd., received the drug registration certificate for Olopatadine Hydrochloride Eye Drops from the National Medical Products Administration [1][2] - The drug is indicated for the treatment of allergic conjunctivitis-related eye itching and was first approved in the United States in 2004, with the original import approval in China granted in 2020 [2] - The domestic market sales of Olopatadine Hydrochloride Eye Drops reached 255 million yuan in 2023, and the company's cumulative R&D investment for this drug is 4.9224 million yuan [2] Group 2 - The approval of the drug registration certificate will help enrich the company's ophthalmic product line [3] - The production and sales of the drug are subject to uncertainties due to industry policies and market competition [3]